At the forefront is the identification of NSD2, a protein whose elevated activity fuels growth in notoriously difficult-to-treat cancers harboring KRAS mutations. KRAS-mutated lung and pancreatic carcinomas have long posed significant therapeutic challenges due to their aggressive behavior and resistance to conventional treatments. Led by Dr. Pawel Mazur, a multi-institutional study has unveiled a new pharmacologic agent capable of targeting NSD2 directly. This drug reprograms chromatin architecture, thereby reversing oncogenic transcriptional programs. Preclinical models demonstrated not only the prevention of tumor progression but also improved survival outcomes when the drug was used independently. Remarkably, combining this NSD2 inhibitor with the KRAS-targeting agent sotorasib induced tumor regression and, in some cases, complete tumor eradication, providing a compelling rationale for clinical translation.

In a separate arena of cancer supportive care, researchers are focusing on the debilitating syndrome of cancer-associated cachexia, characterized by rapid weight loss and muscle wasting. This condition, implicated in approximately one-third of cancer mortality, remains largely untreatable. Dr. Xiling Shen and colleagues have pinpointed the brain-liver axis, specifically the neuroinflammatory disruption of the vagus nerve, as a critical mediator of cachexia. Their investigations revealed that elevated levels of the chemokine CCL2 during cancer progression compromise vagal signaling, impairing liver metabolic functions crucial for maintaining muscle and weight homeostasis. The team explores the novel utilization of non-invasive electronic wearables designed to modulate this neuroinflammatory pathway, offering a promising avenue to mitigate or delay cachexia onset.

Addressing symptomatic management in advanced cancer, the therapeutic efficacy of lorazepam has been revisited in patients experiencing agitated delirium. Dr. David Hui’s NIH-funded Phase II study conducted rigorous patient trials comparing lorazepam, haloperidol, their combination, and placebo interventions. Findings demonstrate that lorazepam alone or combined with haloperidol significantly diminishes agitation levels, outperforming haloperidol monotherapy. This reduces the need for breakthrough dosing and potentially improves quality of life, marking a pivotal shift in delirium management protocols.

Simultaneously, precision oncology advances through machine learning are poised to transform therapeutic decisions in metastatic non-small cell lung cancer (NSCLC). The challenge of selecting between immune checkpoint inhibitor monotherapy or combination chemotherapy has been addressed by Dr. Jia Wu’s team, who developed A-STEP—a sophisticated predictive model incorporating 34 clinical and biological variables from over 2,300 patient cases across multiple centers. This model successfully assessed individual benefit likelihood for combination therapy, recommending treatment alterations in more than half of patients within an external validation cohort. Patients receiving model-informed therapies exhibited notably improved progression-free survival after two years, highlighting the transformative impact of artificial intelligence on oncologic treatment personalization.

Resistance mechanisms remain a formidable barrier in targeting KRAS-driven tumors, with many cancers rapidly developing tolerance to KRAS inhibitors. A study led by Drs. Wantong Yao, Scott Kopetz, and Haoqiang Ying uncovered the pivotal role of the cell surface protein SDC1 in fostering this resistance. Initially downregulated upon therapy, SDC1 expression resurged in resistant pancreatic and colorectal tumors. The oncogene YAP1 was identified as a master regulator within this axis, reactivating SDC1 and downstream receptor tyrosine kinase signaling pathways that drive tumor survival despite KRAS blockade. These insights not only illuminate a fundamental resistance pathway but suggest that targeting the YAP1-SDC1 signaling nexus could potentiate the efficacy and durability of KRAS inhibitors. Furthermore, SDC1 is proposed as a novel biomarker to monitor treatment response and relapse.

For patients battling advanced ovarian cancer, minimal residual disease (MRD) poses a silent but significant threat, often eluding detection despite aggressive frontline therapies. Led by Dr. Amir Jazaeri, investigations utilizing second-look laparoscopy combined with circulating tumor DNA assays revealed that 42.1% of patients harbored residual disease post-treatment. The presence of MRD correlated strongly with poorer progression-free survival. Employing cutting-edge spatial multi-omics, researchers dissected the cellular and molecular architecture of these MRD lesions, identifying critical signaling pathways and potential therapeutic targets. These findings pave the way for more refined, individualized therapeutic strategies aimed at eradicating MRD and enhancing long-term survival in ovarian cancer patients.

Within the realm of hematologic malignancies, myelodysplastic syndromes (MDS) continue to reveal complex biological subtypes with distinct clinical behaviors. The erythroid predominance (EP) subtype, characterized by a high proportion of red blood cell precursors in bone marrow, displays unique genetic signatures, notably a high prevalence of TP53 mutations. Under the guidance of Dr. Guillermo Montalban Bravo, an analysis of 371 MDS patients revealed that EP MDS exhibited aggressive disease features, inferior responses to venetoclax-based therapies, and poorer overall survival. This resistance is hypothesized to stem from elevated BCL-XL protein levels, suggesting a need for novel therapeutic strategies targeting this anti-apoptotic molecule. Three genetically defined subgroups within EP MDS with distinct prognostic outcomes were also delineated, underscoring the heterogeneity and necessity for tailored treatment approaches in this patient population.

Breast cancer research at MD Anderson has also made significant strides in understanding and combating resistance mechanisms. In hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer, CDK4/6 inhibitors have substantially improved outcomes, yet resistance remains a clinical hurdle. Dr. Khandan Keyomarsi’s team revealed that inflammatory signaling driven by elevated interleukin-6 (IL-6) activates STAT3, a transcription factor facilitating tumor progression and drug resistance. Importantly, IL-6 levels can be monitored non-invasively via blood assays, offering a predictive biomarker to identify patients at risk of resistance early. The group further demonstrated that inhibiting the STAT3 pathway in preclinical resistant tumor models suppresses cancer growth, highlighting a promising therapeutic avenue to overcome resistance and improve patient prognosis.

Beyond these scientific advances, MD Anderson Cancer Center recently earned the Advanced Inpatient Diabetes Certification from The Joint Commission, recognizing its excellence in managing diabetes within the inpatient setting. This achievement reflects the institution’s commitment to comprehensive, multidisciplinary patient care extending beyond oncology.

Collectively, these research efforts emphasize the critical importance of interdisciplinary collaboration, integrating molecular biology, immunology, neurology, and computational sciences to accelerate development of novel diagnostics and therapies. The insights gained at MD Anderson not only deepen understanding of cancer biology but also hold transformative potential to improve survival rates and quality of life for patients worldwide. As oncologic paradigms continue to evolve, the center’s commitment to translating laboratory discoveries into clinical innovations remains steadfast, with promising therapies on the horizon for some of the most intractable cancers.

Subject of Research: Cancer research focusing on novel therapeutic targets, treatment resistance mechanisms, diagnostic innovations, and supportive care advancements across lung, pancreatic, ovarian, breast cancers, and myelodysplastic syndromes.

Article Title: MD Anderson Cancer Center Unveils Multidimensional Advances in Cancer Therapeutics and Diagnostics

News Publication Date: August 7, 2025

Web References:

• https://www.mdanderson.org/newsroom/research-highlights.html
• https://www.nature.com/articles/s41586-025-09299-y
• https://www.cell.com/cell/fulltext/S0092-8674(25)00805-0
• https://jamanetwork.com/journals/jamaoncology/fullarticle/2837082
• https://www.nature.com/articles/s41467-025-61823-w#Sec7
• https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00326-X
• https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-0512/763902/Surgical-and-blood-based-minimal-residual-disease
• https://www.nature.com/articles/s41375-025-02711-6
• https://www.nature.com/articles/s41698-025-01041-1

References: See respective journal articles linked above.

Keywords: Cancer research, KRAS mutations, NSD2 inhibitor, cachexia, vagus nerve, lorazepam, delirium, machine learning, non-small cell lung cancer, treatment resistance, SDC1, YAP1, minimal residual disease, ovarian cancer, myelodysplastic syndromes, erythroid predominance, TP53 mutation, venetoclax resistance, CDK4/6 inhibitor resistance, IL-6, STAT3, breast cancer, cancer immunology, precision oncology.

The theme for this year’s ASCO assembly, “Driving Knowledge to Action. Building a Better Future,” underscores the critical nexus between cutting-edge research and patient-centered clinical application. City of Hope’s delegation is poised to contribute robust data sets and innovative research paradigms that spotlight precision oncology, novel therapeutic agents, and advanced management approaches for various malignancies including breast, pancreatic, colorectal, prostate, kidney, and hematologic cancers. Moreover, the emphasis on integrative and supportive care, such as palliative interventions, marks a progressive step towards holistic cancer treatment pathways that prioritize quality of life alongside survival metrics.

Central to City of Hope’s presentations are several key oral abstract and clinical symposium sessions that dissect tumor biology and therapeutic resistance in high-risk renal cell carcinoma. The IMmotion010 study, a randomized phase 3 trial exploring adjuvant atezolizumab versus placebo, will unveil comprehensive genomic characterizations of baseline and post-progression tumors. This analysis promises to elucidate mechanisms of immune evasion and tumor evolution, potentially guiding biomarker-driven treatment algorithms in kidney cancer. Leading this discourse is Dr. Sumanta Kumar Pal, a seasoned medical oncologist with extensive expertise in therapeutic research at City of Hope.

Complementing the genomic insights, City of Hope also emphasizes symptom science and palliative care, acknowledging the indispensable role these disciplines play in oncology. Dr. Tanyanika Phillips will chair a session focusing on the management of cancer-related symptoms and the integration of palliative care principles within standard oncology practice. This aligns with the growing recognition that addressing treatment side effects and symptom burden is fundamental to enhancing patient outcomes and curbing healthcare costs.

Dr. Heather Hampel’s involvement as chair and panelist in a session dedicated to hereditary cancer demonstrates City of Hope’s commitment to genetic risk stratification and precision prevention. By delving deeper into hereditary cancer risk and its clinical repercussions, the session will underscore advances in genetic counseling and germline testing that can personalize cancer surveillance and prophylactic strategies.

Rapid oral abstract sessions will highlight groundbreaking work in breast cancer therapy and hematologic malignancies. The investigation led by Dr. Hope S. Rugo into treatment rechallenge following trastuzumab-deruxtecan-related interstitial lung disease addresses a critical safety and efficacy question in metastatic breast cancer management. Understanding how to safely reintroduce this potent antibody-drug conjugate after pulmonary toxicity could expand therapeutic options for patients with resistant disease.

In leukemia research, Dr. Ibrahim T. Aldoss presents a post hoc analysis from the Phase 3 PhALLCON trial regarding minimal residual disease (MRD) negativity after induction therapy. MRD status serves as a highly sensitive biomarker predictive of relapse and survival, and optimizing treatment to achieve MRD negativity is a paramount goal in acute leukemia management. These findings can expedite the adoption of MRD-guided therapeutic decision-making.

Innovations in myeloma treatment will be critically discussed through City of Hope’s participation as a discussant in sessions exploring novel therapeutic avenues targeting plasma cell dyscrasias. Dr. Amrita Krishnan’s expertise enhances the dialogue surrounding emerging regimens and biomarker-driven interventions aimed at improving long-term disease control and patient quality of life in multiple myeloma.

Educational sessions curated by City of Hope further underscore emerging challenges in oncology. Dr. Hope S. Rugo’s presentation on managing endocrine toxicities serves to equip oncologists with best practices for mitigating adverse effects related to novel breast cancer therapies. This is pivotal as new agents with complex side effect profiles enter clinical use, requiring nuanced management strategies to maintain treatment adherence.

Pediatric oncology survivors’ morbidity reduction is addressed in a session led by Dr. Saro H. Armenian, who advocates for personalized intervention approaches. This focus highlights survivorship care as a critical extension of cancer therapy, addressing long-term consequences of childhood cancer treatment through tailored risk assessment and supportive care techniques.

Integrative oncology is also represented, with Dr. Krisstina Gowin presenting evidence-based guidelines for the management of cancer-associated pain, fatigue, and depression. By operationalizing ASCO’s supportive care guidelines into real-world practice, these sessions promote holistic, patient-centered care models that integrate conventional and complementary modalities.

Poster presentations extend the scope of City of Hope’s research portfolio, showcasing innovative clinical trial data across metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and genitourinary malignancies. Notably, the NAPOLI 3 Phase 3 trial final overall survival analysis in metastatic pancreatic cancer, presented by Dr. Vincent Chung, offers fresh perspectives on treatment efficacy and long-term survival characteristics. Similarly, evaluations of novel immunotherapies and combinatorial regimens in kidney and prostate cancers provide important insights into optimizing sequencing and combination strategies.

Recognition of City of Hope faculty members such as Drs. Lorna Rodriguez-Rodriguez and Stacy W. Gray, who were inducted as fellows of the American Society of Clinical Oncology (FASCO), reflects the institution’s dedication to leadership in oncology research, education, and clinical excellence. This honor acknowledges their pivotal roles in fostering innovation and advancing standards of care to conquer cancer effectively.

City of Hope’s integrated research-to-practice model, underscored by its NCI-designated comprehensive cancer center, continues to influence oncology globally. The institution’s contributions at the 2025 ASCO Annual Meeting epitomize a mission-driven commitment to transforming complex cancer data into actionable clinical applications that improve patient survival and wellbeing. By converging basic science, translational research, and clinical expertise, City of Hope underscores the future of oncology—a future where knowledge unequivocally drives transformative cancer care.

As oncology confronts the challenges of heterogeneity, resistance mechanisms, and survivorship complexities, City of Hope’s broad research landscape—from molecular tumor characterization to supportive care innovation—foreshadows a new horizon in personalized and effective cancer management worldwide.

Subject of Research: Oncology research and clinical advancements across multiple cancer types, including renal cell carcinoma, breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, blood cancers, and supportive care modalities.

Article Title: City of Hope Unveils Pioneering Oncology Research at 2025 ASCO Annual Meeting

News Publication Date: Not specified in the provided content

Web References:

• https://meetings.asco.org/2025-asco-annual-meeting
• https://www.cityofhope.org/

References: Not explicitly provided in the content

Image Credits: Not provided

Keywords: Oncology, Cancer Research, Precision Medicine, Immunotherapy, Hematologic Malignancies, Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Clinical Trials, Supportive Care, Palliative Care